<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">0213264</journal-id>
<journal-id journal-id-type="pubmed-jr-id">1117</journal-id>
<journal-id journal-id-type="nlm-ta">Biol Psychiatry</journal-id>
<journal-id journal-id-type="iso-abbrev">Biol. Psychiatry</journal-id>
<journal-title-group>
<journal-title>Biological psychiatry</journal-title>
</journal-title-group>
<issn pub-type="ppub">0006-3223</issn>
<issn pub-type="epub">1873-2402</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26923505</article-id>
<article-id pub-id-type="pmc">4935637</article-id>
<article-id pub-id-type="doi">10.1016/j.biopsych.2015.12.021</article-id>
<article-id pub-id-type="manuscript">NIHMS749027</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Interactions between Anandamide &amp; Corticotropin-Releasing Hormone Signaling Modulate Human Amygdala Function &amp; Risk for Anxiety Disorders: An Imaging Genetics Strategy for Modeling Molecular Interactions</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Demers</surname>
<given-names>Catherine H.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Conley</surname>
<given-names>Emily Drabant</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bogdan</surname>
<given-names>Ryan</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hariri</surname>
<given-names>Ahmad R.</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Psychological and Brain Sciences, Washington University in St. Louis, St. Louis, MO, USA</aff>
<aff id="A2"><label>2</label>23andMe, Inc., Mountain View, CA, USA</aff>
<aff id="A3"><label>3</label>Division of Biology and Biomedical Sciences, Washington University in St. Louis, St. Louis, MO, USA</aff>
<aff id="A4"><label>4</label>Laboratory of NeuroGenetics, Department of Psychology and Neuroscience, Duke University, Durham, NC, USA</aff>
<author-notes>
<corresp id="FN1">Corresponding Author: Ryan Bogdan, Ph.D., Campus Box 1125, Psychology Bldg. Washington University in St. Louis, One Brookings Dr., St. Louis, MO 63130, USA, <email>rbogdan@wustl.edu</email></corresp>
<fn fn-type="conflict" id="FN3">
<p>The authors declare no competing financial interests.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>16</day>
<month>1</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>05</day>
<month>1</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<day>1</day>
<month>9</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>9</month>
<year>2017</year>
</pub-date>
<volume>80</volume>
<issue>5</issue>
<fpage>356</fpage>
<lpage>362</lpage>
<!--elocation-id from pubmed: 10.1016/j.biopsych.2015.12.021-->
<abstract>
<sec id="S1">
<title>Background</title>
<p id="P2">Preclinical models reveal that stress-induced amygdala activity and impairment in fear extinction reflects reductions in anandamide driven by corticotropin-releasing hormone receptor type 1 (CRHR1) potentiation of the anandamide catabolic enzyme fatty acid amide hydrolase (FAAH).</p>
</sec>
<sec id="S2">
<title>Methods</title>
<p id="P3">Here we provide clinical translation for the importance of these molecular interactions using an imaging genetics strategy to examine whether interactions between genetic polymorphisms associated with differential anandamide (<italic>FAAH</italic> rs324420) and CRHR1 (<italic>CRHR1</italic> rs110402) signaling modulate amygdala function and anxiety disorder diagnosis.</p>
</sec>
<sec id="S3">
<title>Results</title>
<p id="P4">Analyses revealed that individuals with a genetic background predicting relatively high anandamide <italic>and</italic> CRHR1 signaling exhibited blunted basolateral amygdala habituation, which further mediated increased risk for anxiety disorders amongst these same individuals.</p>
</sec>
<sec id="S4">
<title>Conclusions</title>
<p id="P5">The convergence of preclinical and clinical data suggests that interactions between anandamide and CRHR1 represent a fundamental molecular mechanism regulating amygdala function and anxiety. Our results further highlight the potential of imaging genetics to powerfully translate complex preclinical findings to clinically meaningful human phenotypes.</p>
</sec>
</abstract>
<kwd-group>
<kwd>anxiety</kwd>
<kwd>amygdala</kwd>
<kwd>FAAH</kwd>
<kwd>CRHR1</kwd>
<kwd>habituation</kwd>
<kwd>imaging genetics</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>